Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.
Target Price
The average target price of STX.L is 16 and suggests 90% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell